





Successful Global Public Private Partnerships

Timothy N.C. Wells, CSO

Geneva Forum May 28th 2008

Curing Malaria Together

www.mmv.org



Medicines for Malaria Venture

Key success factors for Product Development Partnerships

Effective partnerships synergize the best from the private and public sector. MMV successfully develops antimalarials by


- Robust portfolio management: catalyzing, selecting, remodeling and terminating projects based on their relative merits
- Raising and allocating philanthropic and public funds to projects
- Integrating and coordinating world class industry with academic science and medicine – international thought leaders as advisors
- Ensuring new medicines meet the needs of our patients and are accessible: interactions with public sector and endemic-country stakeholders



MMV has a wide panel of donors

MMV - Medicines for Malaria Venture
funding from Foundation to 2010 (May 2006)

(Total Received/Pledged \$263 Million)



MMV Portfolio: May 2008

Research		Translational			Development	
Discovery	Lead Opt	Preclinical	Phase I	Phase II	Phase III	Registration
Novartis 9 projects	Ozonides	Isoquine	Tafenoquine	IV artesunate	Eurartesim	Coartem-D
GSK 3 projects	DHFR	MK 4815			Pyramax	
Broad/Genzyme 5 projects	Pyridones	Pyridone 932121				
Others 6 projects	Macrolides					
	DHODH					
	Falcipain Inhibitors					

Likelihood to
Launch (CMR)

7%

14%

27%

38%




72%



What does success look like?

New Products meeting unmet medical needs

- **Low hanging fruit to 2010**
 - Harvesting the work of the last 20 years – the ACTs
 - **Key:** safety as well as efficacy
- **Longer term – new tools for elimination**
 - New validated targets – progress from the genome
 - New industrial biology: erythrocytes, liver stages, gametocytes



Key Collaborations

- **Late Stage Development: Novartis, GSK, Sigma Tau, Holleypharm, Shin Poong, (Sanofi)**
- **Mini-portfolios: GSK Tres Cantos, Novartis NITD, Broad/Genzyme**
- **Academic Collaboration networks: WRAIR, WHO-TDR, Monash, USC, etc**

- **Special thanks to J Carl Craft MD and Robert G Ridley PhD**

